Galapagos NV
GLPG
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$31.53
Price+1.06%
$0.33
1Y
Price
Market Cap
$2.078b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-154.9%
EBITDA Margin-162.0%
Net Profit Margin-173.0%
Free Cash Flow MarginRevenue
$275.609m
+0.0%
1y CAGR-12.5%
3y CAGR-8.3%
5y CAGREarnings
-$284.274m
-483.7%
1y CAGR-117.2%
3y CAGR-106.4%
5y CAGREPS
-$4.39
-21850.0%
1y CAGR-7228.4%
3y CAGR-5439.7%
5y CAGRBook Value
$2.644b
$3.818b
Assets$1.174b
Liabilities$8.443m
DebtDebt to Assets
0.2%
-
Debt to EBITDAFree Cash Flow
-$297.684m
+26.0%
1y CAGR+17.4%
3y CAGR+14.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company